Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 71205-557

7 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71205-557). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability over time of achieving an initial headache response within 2 hours post-dose. The graph compares placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg, with increasing response probabilities over time for higher doses.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg strengths) or placebo for migraine relief over 24 hours following the initial treatment dose. The y-axis indicates estimated probability of medication rescue, and the x-axis represents hours post-dose. The graph compares placebo, 5 mg, and 10 mg Rizatriptan Benzoate tablets in pooled clinical studies.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response over 2 hours post-dose for Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The x-axis represents hours post-dose (0 to 2 hours), and the y-axis shows the estimated probability of response (0% to 100%). The graph depicts higher response probabilities for Rizatriptan Benzoate tablets versus placebo.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)
A Kaplan-Meier curve chart showing the estimated probability over 24 hours of patients taking a second dose of Rizatriptan Benzoate orally disintegrating tablets or other medication for migraines. The graph compares placebo, 5 mg, and 10 mg doses of Rizatriptan Benzoate OD tablets, with the x-axis representing hours post-dose and the y-axis representing the probability of medication or rescue use.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line graph titled 'Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7' comparing Rizatriptan Benzoate OD Tablets versus Placebo over time. The x-axis represents hours post dose (0.5 to 2 hours), and the y-axis shows the percentage of patients with no headache pain (0 to 100%). Rizatriptan Benzoate OD Tablets are indicated with a solid line and show a higher percentage of patients reporting no headache pain compared to placebo, represented by a dashed line, at each time point.*
FDA Label Image

71205-557-06 (Rizatriptan Fig7)

71205-557-06 (Rizatriptan Fig7)
Label for Rizatriptan Benzoate ODT 10 mg orally disintegrating tablets by Proficient Rx LP. The label shows NDC 71205-557-06, single blister card pack of 6 tablets. Each tablet contains 14.53 mg rizatriptan benzoate equivalent to 10 mg rizatriptan. Distributed by Rising Health, LLC, made in India, with storage instructions and lot number placeholders.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure of the active ingredient Rizatriptan Benzoate, showing its molecular components and arrangement as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.